The Inhibitory Effect of Validamycin A on Aspergillus flavus

Table 1

Minimum inhibitory concentrations (MICs) of validamycin A alone, amphotericin B alone, or validamycin A in combination with amphotericin B on Aspergillus flavus ATCC204304 and Aspergillus flavus from clinical isolates. The table also contains patient characteristics, i.e., specimen source, diagnosis, and underlying disease, including the fractional inhibitory concentration index (FICI) and the interpretation of FICI (interpretation: (A) additive; (S) synergistic).

A. flavus strains	Specimen	Diagnosis (EORTC criteria)	Underlying disease	MICs of the single agent (μg/mL)		MICs of combined agents (μg/mL)		FICI (μg/mL)	Interpretation
				Validamycin A	Amphotericin B	Validamycin A	Amphotericin B
A. flavus ATCC204304	Human sputum			1	4	0.125	2	0.625	A
A. flavus SI 1	Left sphenoid sinus	Invasive aspergillosis (probable invasive aspergillosis)	Diabetes, hypertension, and dyslipidemia	>128	8	0.125	2	<0.251	S
A. flavus SP 2	Sputum	Invasive pulmonary aspergillosis (possible invasive aspergillosis)	Hepatitis C virus cirrhosis	1	8	0.0312	2	0.281	S
A. flavus EN 3	Endotracheal aspiration	Invasive pulmonary aspergillosis (probable invasive aspergillosis)	Acute lymphoblastic leukemia	>128	8	0.0039	2	<0.250	S